Ovarian Cancer is the 9th most common cancer in the world 1, and Europe has the highest rates of ovarian cancer in the world 2. Although the cancer antigen 125 (CA 125) assay has been used for more ...

Aspira Women’s Health Inc. AWH has taken a significant step forward in advancing the clinical treatment of adnexal masses by entering into a definitive agreement with Dorsata, a healthcare software ...

Please provide your email address to receive an email when new articles are posted on . Four adnexal mass classification algorithms successfully distinguished lesions when used by a novice operator. A ...

Three-dimensional power Doppler (3DPD) ultrasound has been used for assessing adnexal masses, and in this study, we aimed to perform a meta-analysis to evaluate its role in the differential diagnosis ...

Three-dimensional power Doppler (3DPD) ultrasound has been used for assessing adnexal masses, and in this study, we aimed to perform a meta-analysis to evaluate its role in the differential diagnosis ...

Ovarian tumours and adnexal masses encompass a broad spectrum of pathologies, ranging from benign cysts to aggressive malignancies. Accurate and early diagnosis is critical due to the high mortality ...

Multivariate index assay (MIA3G) to reduce preventive surgery for ovarian cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text ...

AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced its manuscript, ...

AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease ...

Current clinical methods used to identify epithelial ovarian cancer are often too late – when the cancer is at an advanced stage, leaving the patient with limited therapeutic options. Diagnosis is ...